AppYea

AppYea Short-term Debt

Delisted·Sep 22, 2026

The Short-Term Debt of AppYea (APYP) as of Nov 4, 2026 is 2.34 M USD. In the previous year, Short-Term Debt was 2.17 M USD — a change of 7.89% (higher).

Short-term Debt

2.34 MUSD

YoY

7.89%

Last updated:

Short-Term Debt of AppYea is 2022 2.34 M USD. Short-Term Debt of AppYea was 2021 2.17 M USD. It decreases by 7.89% higher compared to the previous year.

The AppYea Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2014
26,000.00 USD
Jan 1, 2015
73,636.00 USD
Jan 1, 2016
454.00 USD
Jan 1, 2017
174,904.00 USD
Jan 1, 2018
387,887.00 USD
Jan 1, 2019
403,456.00 USD
Jan 1, 2021
2.17 M USD
Jan 1, 2022
2.34 M USD
The AppYea Short-term Debt history
YEARShort-term DebtYoY
2.34 MUSD+7.89%
2.17 MUSD+436.86%
403,456.00USD+4.01%
387,887.00USD+121.77%
174,904.00USD+38,425.11%
454.00USD-99.38%
73,636.00USD+183.22%
26,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AppYea Stock analysis

What does AppYea do? AppYea Inc develops wearable monitoring solutions for sleep apnea and snoring treatment, focusing on the DreamIT wristband for snoring biofeedback and the DreamIT PRO wristband for sleep apnea treatment. The SleepX App monitors physiological parameters during sleep using algorithms developed by SleepX, while SleepX PRO is a medical application that identifies sleep apnea episodes without direct user contact. These products target patients seeking non-invasive sleep disorder management through wearable technology. The company's revenue streams come from direct sales of DreamIT, DreamIT PRO, and SleepX PRO to end-users, with the SleepX PRO app specifically positioned as a medical application for sleep apnea monitoring. The DreamIT and DreamIT PRO devices are sold alongside their respective apps, creating a bundled offering for consumers managing sleep-related health issues. The SleepX PRO app's medical certification enables it to be marketed as a healthcare solution rather than a general wellness tool. AppYea Inc's target market includes individuals diagnosed with sleep apnea or chronic snoring, who prefer wearable technology over traditional CPAP machines. The company positions its products as alternatives to conventional treatments, emphasizing convenience and non-invasive monitoring through the SleepX algorithms that process sensor data during sleep. Sales are driven by the medical application status of SleepX PRO, which differentiates it from consumer wellness apps. AppYea is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AppYea stock

Short-Term Debt of AppYea is 2.34 M USD in 2022.

Short-Term Debt of AppYea changed from 2.17 M USD to 2.34 M USD, representing a 7.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt AppYea since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's AppYea historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — AppYea

All Key Metrics — AppYea